OBJECTIVES: According to the recent international data, the incidence of bloodstream catheter-associated infections is 3-8% in the structure of hospital-acquired infections in the intensive care units (ICU) and the leading cause of them are Gram positive bacteria. In this study we conducted comparative analysis of clinico-economic effectiveness of daptomycin (dapto) vs. vancomycin (vanco) usage in treatment of patients with MRSA catheter-associated infection in the ICU. METHODS: "Decision Tree" pharmacoeconomic model was built based on results of international clinical studies and data of routine practice treatment of bloodstream infections in Moscow clinics. Two variants of antibacterial treatment of patients with catheter-associated infections differing on starting products (dapto or vanco) were assessed. If the fi rst line of therapy was ineffective, patients switched over to the second line therapy covering resistant strains-meropenem and fl uconazole. Direct and indirect medical costs were assessed: cost of antibiotics and additional medical treatment, antibacterial diagnostic, laboratory and cost of bed-days in ICU and therapeutic department. Costs were based on offi cial data on hospital medical service in municipal Moscow clinics and purchasing price on medical products from price list of the biggest Russian pharmaceutical distributors. Clinical recovery was considered as effi cacy with the goal to evaluate cost-effectiveness ratio (CER) of two groups (CERdapto and CERvan accordingly). RESULTS: Better clinical effi cacy in daptomycin group resulted in lowerneeds to change antibiotic in catheter-associated infection treatment in the ICU in comparison to vancomycin group. In spite of the higher price of drug, average cost of successfully treated patient by daptomycin (CERdapto) was 227,887 RUR/pt in compare with CERvan 235,032 RUR/pt. Exchange rate is 1USD = 30 RUR. CON-CLUSIONS: Good cost-effectiveness ratio in comparison to vancomycin supports use of daptomycin as the fi rst line antibacterial therapy in bloodstream catheter-associated infections.
The clinical and quality of life data were obtained from published literature and re-confi rmed based on a questionnaire survey from a clinical expert panel of 20 hepatitis B specialists. From the perspective of China's health insurance system, cost data was calculated based on the published literature about economic burden of chronic hepatitis B. a discounting rate at 3% was used to discount utilities and medical costs happened at different years. a univariate sensitivity analysis was performed to understand the key drivers and general sensitivity of the model. RESULTS: The model results showed that the utilization of 1 year peginterferon alfa-2a treatment for HBeAg-positive CHB can prolong 0.32 QALYs, compared to the 4 years entecavir treatment (16, 394 QALYs vs. 16, 074 QALYs) . The total cost per patient treated with peginterferon alfa-2a was US$22,221, and US$19,989 for patient treated with entecavir. The discounted incremental cost per QALY gained for pegainterferon alfa-2a was US$6965. CONCLU-SIONS: The results of the model suggest that 1 year pegainterferon alfa-2a improves health outcomes in a cost-effective manner compared with 4 years entecavir in the treatment of HBeAg-positive chronic hepatitis B in China.
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COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B BOTH PLUS RIBAVIRIN IN SPAIN
Ventayol-Bosch P 1 , Rubio-Terrés C 2 , García-Samaniego J 3 , Planas R 4 , Solà-Lamoglia R 5 , Romero-Gómez M 6 , Diago-Madrid M 7 , Crespo-García J 8 , Calleja-Panero JL 9 , Turnes-Vázquez J 10 1 Hospital Universitario Son Dureta, Palma de Mallorca, Spain; 2 HealthValue, Madrid, Spain; 3 Hospital Carlos III, CIBEREHD, Madrid, Spain; 4 Hospital Germans Trias i Pujol, CIBEREHD, Barcelona, Spain; 5 Hospital del Mar (IMIM), Barcelona, Spain; 6 Hospital Universitario de Valme, CIBEREHD, Sevilla, Spain; 7 Hospital General Universitario de Valencia, Valencia, Spain; 8 Hospital Universitario Marqués de Valdecilla, Santander, Spain; 9 Hospital Universitario Puerta de Hierro, Madrid, Spain; 10 Complejo Hospitalario de Pontevedra, Pontevedra, Spain OBJECTIVES: To estimate long-term cost-effectiveness of treatment of chronic hepatitis C (CHC) patients with peginterferon alfa-2a (180 mcg/week) versus peginterferon alfa-2b (1.5 mcg/kg/week) both in combination with ribavirin (800-1400 mg/day) from the Spanish National Healthcare System perspective. METHODS: A metaanalysis of head-to-head randomized trials of peginterferon alfa-2a and peginterferon alfa-2b both plus ribavirin, evaluating sustained virological response (SVR) has been recently published. It showed RR = 1.11 (95%CI 1.04-1.19) for all genotypes, RR = 1.21 (95%CI 1.03-1.42) for G-1/4, and RR = 1.11 (95%CI 1.02-1.22) for G-2/3. a Markov model with 7 health states was developed to simulate the disease progression of adult patients with CHC for a lifetime horizon. Effi cacy, in terms of SVR, was calculated from the meta-analysis, showing a better SVR rate for peginterferon alfa-2a than for peginterferon alfa-2b: the absolute differences were of 6.0%; 7.6%; and 8.7% for all genotypes, G-1/4 and G-2/3 respectively. Transition probabilities and health states utilities were obtained from published literature. Health direct costs of peginterferon + ribavirin (48 weeks for G-1/4 and 24 weeks for G-2/3) and of disease complications were collected from Spanish databases and studies ([c] 2010). The annual discount rate was 3.5% for costs and outcomes. RESULTS: Each patient gained 0.469, 0.600 and 0.685 life-years (LY) and 0.155, 0.198 and 0.227 qualityadjusted life-years (QALY) with peginterferon alfa-2a in comparison with peginterferon alfa-2b, for all genotypes, G-1/4 and G-2/3 respectively. The savings per patient treated with peginterferon alfa-2a were c705, c672 and c1900, for all genotypes, G-1/4 and G-2/3, respectively. Peginterferon alfa-2a was the dominant treatment strategy (lower costs and higher effi cacy than peginterferon alfa-2b treatment). CONCLUSIONS: Treatment of patients with chronic hepatitis C with peginterferon alfa-2a + ribavirin is a cost-effective strategy in comparison with peginterferon alfa-2b + ribavirin for all genotypes, G-1/4 and G-2/3.
PIN46 KIOVIG FOR PRIMARY IMMUNODEFICIENCY: REDUCED INFUSION AND DECREASED COSTS PER INFUSION
Connolly M 1 , Simoens S 2 1 Global Market Access Solutions, St Prex, Switzerland; 2 K.U. Leuven, Leuven, Belgium OBJECTIVES: Kiovig is a new, ready-to-use 10% liquid immunoglobulin preparation that is medically indicated for the treatment of primary immunodefi ciency. This study aims to conduct an economic evaluation which compares the intravenous immunoglobulin (IVIg) preparations Kiovig, Multigam, and Sandoglobulin from the Belgian societal perspective. METHODS: Given that three prospective studies have observed no difference in outcomes, a cost-minimization analysis considered the differences in costs that can arise from these immunoglobulin products. a decision-analytic model simulated immunoglobulin treatment over a one-year time horizon. Cost items included immunoglobulin costs, pharmacy administration and nursing costs, miniforfait paid for hospital infusion, costs of adverse events, and lost productivity. Cost data were identifi ed from published sources and Belgian hospital administrators. a probabilistic sensitivity analysis explored the impact of parameter uncertainty. The price year was 2009. RESULTS: Costs per infusion cycle in adult primary immunodefi ciency patients were c1.046 (95% confi dence interval: c1.006-1.093) with Kiovig; c1.102 (c1.064-1.147) with Multigam; and c1.147 (c1.108-1.193) with Sandoglobulin. The average cost savings per infusion with Kiovig as compared to Multigam and Sandoglobulin amounted to c56 and c101 per infusion. CONCLUSIONS: Treatment costs with Kiovig were shown to be lower as compared to other IVIgs in Belgium. Reduced costs per infusion were attributed to lower costs associated with treating adverse events and the opportunity cost of nursing time and time off work for working adults.
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COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL VACCINES IN TAIWAN
Chang CJ 1 , Wang PC 2 , Huang YC 3 , Wu BS 4 , Wu CL 1 , Topachevskyi O 5 , Jung W 6 1 Chang Gung University, Taoyuan, Taiwan; 2 Cathay General Hospital, Taipei, Taiwan; 3 Chang Gung Memorial Hospital, Taoyuan, Taiwan; 4 National Yang-Ming University, Taipei, Taiwan; 5 GlaxoSmithKline Biologicals, Wavre, Belgium; 6 GlaxoSmithKline, Singapore, Singapore OBJECTIVES: To evaluate cost-effectiveness of pneumococcal non-typeable Haemophilus Infl uenza protein D conjugate vaccine(PHiD-CV), 7-valent pneumococcal conjugate vaccine(PCV7), and PCV13 in Taiwan. METHODS: An age-compartmental, deterministic, static cohort model simulated in a 198,733 birth cohort the disease process of invasive disease(ID, meningitis and bacteremia), community acquired pneumonia(CAP), and acute otitis media(AOM) over life-time. The model was developed by GlaxoSmithKline and adapted with local data. For base-case analysis for all vaccines, a 4-dose(3 + 1) schedule was assumed with 95% vaccine coverage. Cost and outcomes were analyzed from health care payer perspective with 3% discount rate. Herd protection on ID, limited cross protection against 6A and 19A, minimal estimation of NTHi(non-typeable Haemophilis Infl uenzae) infection rates in ID and CAP were assumed for base case. Costs for PHiD-CV, PCV7 and PCV13 were assumed parity at 3200 New Taiwan Dollar(NTD). Epidemiological and cost data were obtained from local disease burden study. Vaccine effi cacy data were obtained from published sources. One way and probabilistic sensitivity analyses were conducted. RESULTS: Compared with PCV7, PHiD-CV is expected to prevent additional cases of 1 ID, 2,291 CAP and 63,597 AOM, with 548 additional quality-adjusted lifeyears(QALY) gained with total saving of NTD 69,347,211. Compared with PCV13, PHiD-CV is expected to prevent less cases of 4 ID and 264 CAP, but expected to prevent additional 45,111 AOM cases. PHiD-CV is expected to provide additional 181 QALY gained with total saving of NTD 14,532,124 compared to PCV13. Sensitivity analyses show the results are most sensitive to the changes of AOM related parameters, but when the AOM related parameters were changed up to +/− 20%, PHiD-CV is still cost-saving to PCV7 and PCV 13. CONCLUSIONS: PHiD-CV is expected to provide more QALYs with potential saving of total health care cost
